AIM ImmunoTech (AIM) Gains from Investment Securities (2014 - 2026)
AIM ImmunoTech's (AIM) quarterly Gains from Investment Securities came in at $468000.0 in Q1 2026, down 50.32% on a QoQ basis from $942000.0 in Q4 2025.
AIM ImmunoTech (AIM) Gains from Investment Securities (2014 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 10 years of Gains from Investment Securities data on file, last reported at $468000.0 in Q1 2026.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $468000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $740000.0 (changed N/A YoY) and the FY2025 annual result came in at $272000.0, down 40.61% from the prior year.
- Gains from Investment Securities eased to $468000.0 in Q1 2026, from $942000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $942000.0 in Q4 2025 to a low of -$670000.0 in Q3 2025.
- A 3-year average of $117500.0 and a median of -$2000.0 in 2022 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 98.04% in 2022, down 183.78% in 2022.
- Tracing AIM's Gains from Investment Securities over 3 years: stood at -$1000.0 in 2022, then jumped by 94300.0% to $942000.0 in 2025, then plunged by 50.32% to $468000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $468000.0 (Q1 2026), $942000.0 (Q4 2025), and -$670000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,000.00 |
| Mar 31, 2026 | 468,000.00 |
| Dec 31, 2025 | 942,000.00 |
| Dec 31, 2025 | 942,000.00 |
| Sep 30, 2025 | -670,000.00 |
| Sep 30, 2025 | -670,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | -3,000.00 |
| Jun 30, 2022 | -3,000.00 |
| Mar 31, 2022 | -31,000.00 |
| Mar 31, 2022 | -31,000.00 |
| Dec 31, 2021 | -123,000.00 |
| Dec 31, 2021 | -123,000.00 |
| Sep 30, 2021 | -51,000.00 |
| Sep 30, 2021 | -51,000.00 |
| Jun 30, 2021 | -7,000.00 |
| Jun 30, 2021 | -7,000.00 |
| Mar 31, 2021 | 37,000.00 |
| Mar 31, 2021 | 37,000.00 |